Beyond pain relief: rethinking sleep outcomes in CGRP-targeted migraine therapy.

CGRP-targeted therapies have changed how we treat migraines, but their impact on sleep isn’t fully clear. This review looks at recent studies on sleep outcomes with these therapies. These treatments include monoclonal antibodies and gepants. Some studies suggest that patients experience better sleep after using these therapies. However, the evidence is still limited and not definitive. There are few reported negative effects on sleep from these treatments. It’s unclear if sleep improvements come from CGRP pathway changes or better migraine control. Additionally, patient differences complicate the findings. Factors like sleep disorders, mental health issues, chronic pain, and other medications play a role. Future research should focus on detailed sleep assessments and long-term studies. This will help determine if CGRP-targeted therapies really affect sleep quality or just how patients perceive their sleep. Clinical relevance: This research highlights the need for better understanding of CGRP-targeted therapies’ effects on sleep, potentially guiding treatment decisions for migraine patients.